NEW YORK, Jan. 14, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether NeoGenomics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 31, 2023, NeoGenomics’ competitor, Natera, Inc. (“Natera”), announced that it had sued NeoGenomics in federal court, alleging that the Company’s cancer test, the RaDaR molecular residual disease assay, infringed Natera’s patents.
Then, on December 27, 2023, Natera announced that the federal court had issued a preliminary injunction, effective immediately, barring NeoGenomics from making, using, selling, or promoting the RaDaR test, but that NeoGenomics may continue to offer RaDaR to existing patients and for clinical trials, studies, or projects already in process.
The following day, NeoGenomics acknowledged the preliminary injunction, announcing that it would appeal the federal court’s ruling.
On this news, NeoGenomics’ stock price fell $3.71 per share, or 18.1%, to close at $16.79 per share on December 28, 2023.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
